Metabolic Messengers: glucagon-like peptide 1
The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
Glucagon like peptide-1 (GLP-1), a peptide hormone from the intestinal tract, plays a central role in the coordination of postprandial glucose homeostasis through actions on insulin secretion, food intake and gut motility. GLP-1 forms the basis for a variety of current drugs for the treatment of type 2 diabetes and obesity, as well as new agents currently being developed. Here, we provide a concise overview of the core physiology of GLP-1 secretion and action, and the role of the peptide in human health, disease and therapeutics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gut-derived (peripheral) GLP-1 is best known as an incretin hormone, released postprandially from L-cells and acting on pancreatic β-cell GLP-1R to increase glucose-dependent insulin secretion—the action underlying the therapeutic value of potentiating GLP-1 signaling for the treatment of type 2 diabetes (24, 25).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [25]
In the citing paper
“The density of L-cells increases toward the distal end of the gastrointestinal tract, peaking in the ileum and colon—a paradoxical observation given that nutrient-sensing cell density would be expected to be highest in the proximal intestine where nutrient absorption primarily takes place (25, 33).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [25]
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationCheng, H., & Leblond, C. P. (1974) · American Journal of Anatomy · doi:10.1002/aja.1001410407 · Cited by 1,735
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Cited by
Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target
Wang, K., Zhang, Z., Hang, J., Liu, J., Guo, F., Ding, Y., Li, M., Nie, Q., Lin, J., Zhuo, Y., et al. (2023) · Science · doi:10.1126/science.add5787 · Cited by 173
Kabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126
“Although GLP-1 deficiency maybe unlikely to contribute to impaired insulin action in type 2 diabetes (Gribble & Reimann, 2021), low GLP-1 levels are a potential risk factor in the development of type 2 diabetes (Lastya et al., 2014).”
BackgroundResultShort‐chain fatty acids: bridges between diet, gut microbiota, and health
Wang, L., He, L., Xu, L., & Li, S. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16619 · Cited by 157
“28 Besides, SCFAs stimulate the secretion of glucagon-like peptide-1 (GLP-1) via GPR43 on IECs, suppressing gastric emptying and reducing appetite 29 (Fig.”
Metformin-based nanomedicines for reprogramming tumor immune microenvironment
Liu, J., Li, X., Li, Y., Gong, Q., & Luo, K. (2024) · Theranostics · doi:10.7150/thno.104872 · Cited by 123
“The most acknowledged anti-diabetic mechanisms of metformin involve in reducing hepatic gluconeogenesis and increasing intestinal secretion of glucagon-like peptide 1 (GLP1) through activating the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway [17, 18].”
GLP-1a: Going beyond Traditional Use
Laurindo, L. F., Barbalho, S. M., Guiguer, E. L., da Silva Soares de Souza, M., de Souza, G. A., Fidalgo, T. M., Araújo, A. C., de Souza Gonzaga, H. F., de Bortoli Teixeira, D., de Oliveira Silva Ullmann, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020739 · Cited by 102
Metadata
- Authors
- Gribble, F. M., & Reimann, F.
- Affiliations
- Wellcome/MRC Institute of Metabolic Science (GB)
- Corresponding author
- Gribble, Fiona M.
- Reimann, Frank
- Venue
- Nature Metabolism
- Published
- 2021-01-11
- Volume
- 3
- Issue
- 2
- Pages
- 142-148
- ISSN
- 2522-5812 (ISSN-L)
- OpenAlex
- W3119033633
- Cited by
- 199
- References
- 100
- Citations by year
- 2026: 29 · 2025: 48 · 2024: 53 · 2023: 28 · 2022: 28 · 2021: 13
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust (106262/Z/14/Z, 106263/Z/14/Z)
- RCUK | Medical Research Council (MRC_MC_UU_12012/3)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, GLP-1 secretion, insulin secretion, food intake regulation, intestinal motility, type 2 diabetes, obesity, GLP-1 receptor agonists, incretins
- MeSH terms
- Animals, Gastrointestinal Hormones, Humans, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic Messengers: glucagon-like peptide 1. https://app.cochat.ai/papers/10.1038/s42255-020-00327-x
- The paper
- Gribble, F. M., & Reimann, F. (2021). Metabolic Messengers: glucagon-like peptide 1. Nature Metabolism. https://doi.org/10.1038/s42255-020-00327-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.